Abstract:Traditional High-Throughput Screening (HTS) drug discovery is inefficient. Hit rates for compounds with clinical therapeutic potential are typically 0.5% and only up to 2% maximally. Deep learning models have enriched screening rates to 28%; however, these results include hits with non-therapeutic relevant concentrations, insufficient novelty to their training set, and traverse limited chemical space. This study introduces a novel artificial intelligence (AI)-driven platform, GALILEO, and the Molecular-Geometric Deep Learning (Mol-GDL) model, ChemPrint. This model deploys both t-distributed Stochastic Neighbor Embedding (t-SNE) data splitting to maximize chemical dissimilarity during training and adaptive molecular embeddings to enhance predictive capabilities and navigate uncharted molecular territories. When tested retrospectively, ChemPrint outperformed a panel of five models for the difficult-to-drug oncology targets, AXL and BRD4, achieving an average AUROC score of 0.897 for AXL and 0.876 for BRD4 using the t-SNE split, compared to benchmark model scores ranging from 0.826 to 0.885 for AXL and 0.801 to 0.852 for BRD4. In a zero-shot prospective study, in vitro testing demonstrated that 19 of 41 compounds nominated by ChemPrint against AXL and BRD4 demonstrated inhibitory activity at concentrations ≤ 20μM, a 46% hit rate. The 19 hits reported an average-maximum Tanimoto similarity score of 0.36 relative to their training set and scores of 0.13 (AXL) and 0.10 (BRD4) relative to clinical stage compounds for these targets. Our findings demonstrate that increasing test set difficulty through training and testing ChemPrint on datasets with maximal dissimilarity enhances the predictive capabilities of the model. This results in the discovery of compound libraries at high hit rates with low therapeutic concentrations and high chemical novelty. Taken together, the proposed platform sets a new performance standard.

Illuminator: increasing synergies between medicinal and computational chemists

IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads

Integrated Molecular Modeling and Machine Learning for Drug Design

SynthFormer: Equivariant Pharmacophore-based Generation of Molecules for Ligand-Based Drug Design

MolHyb: A Web Server for Structure-Based Drug Design by Molecular Hybridization

CASTELO: Clustered Atom Subtypes aidEd Lead Optimization -- a combined machine learning and molecular modeling method

Decipher Fundamental Atomic Interactions to Unify Generative Molecular Docking and Design

ChemoDOTS: a web server to design chemistry-driven focused libraries

A Practical Guide to Molecular Docking and Homology Modelling for Medicinal Chemists

Metis - A Python-Based User Interface to Collect Expert Feedback for Generative Chemistry Models

AMPL: A Data-Driven Modeling Pipeline for Drug Discovery

Implementation of an Automated System Using Machine Learning Models to Accelerate the Process of In Silico Identification of Small Molecules As Drug Candidates

ACID: a free tool for drug repurposing using consensus inverse docking strategy

Molecular docking as a popular tool in drug design, an in silico travel

Pharmaceutical Cocrystal Discovery via 3D-SMINBR: A New Network Recommendation Tool Augmented by 3D Molecular Conformations

MolOptimizer: A Molecular Optimization Toolkit for Fragment-Based Drug Design

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic

Integrated Modeling Program, Applied Chemical Theory (IMPACT)

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery

The AI-driven Drug Design (AIDD) platform: an interactive multi-parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations